Polidocanol Sclerotherapy of Pharynges for Obstructive Sleep Apnea (OSA) and Snoring Subjects(SS)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2006 by Liaoyang Central Hospital.
Recruitment status was Not yet recruiting
Information provided by:
Liaoyang Central Hospital
First received: November 13, 2006
Last updated: November 20, 2006
Last verified: November 2006
The aim of this prospective study is to evaluate the results of polidocanol sclerotherapy of pharynx for OSAS & SS,to reduce pharyngeal compliance.
Drug: Polidocanol Sclerotherapy
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Preliminary Study on Submucous Sclerosis of Pharynges With 1% Polidocanol to Treat Obstructive Sleep Apnea (OSA) & Snoring Subjects (SS)
Primary Outcome Measures:
- apnea-hypopnea index (AHI)is on polysomnography(PSG),to compare AHIanterior and posterior treatment.
Secondary Outcome Measures:
- Arterial oxygen saturation (SaO2) and body mass index (BMI)will be measured on polysomnography
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
Polidocanol submucous sclerosis in the part of pharynges with 1% polidocanol injection.The injection should be in the retropharyngeal submucosa and lateral pharyngeal bands and lateral pharyngeal submucosa and in front submucosa of soft palate.The injection is multi-point,and each point injection is 0.3~0.5ml;the total quantity/each time is not more than 5ml.Every patient have to be treated about 1~2 time.
|Ages Eligible for Study:
||18 Years to 65 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- OSAS & SS which palatopharyngeal collapse.
- obstructive sleep apnea syndrome (osas) & snoring subjects (ss),which anatomic narrow result in.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00399451
Liaoyang Central Hospital
||Youliang YIN, MB
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||November 13, 2006
||November 20, 2006
||China: Ministry of Health
Keywords provided by Liaoyang Central Hospital:
apnea-hypopnea index (AHI)
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 16, 2015
Sleep Apnea, Obstructive
Nervous System Diseases
Respiratory Tract Diseases
Signs and Symptoms
Signs and Symptoms, Respiratory
Sleep Apnea Syndromes
Sleep Disorders, Intrinsic